Efficacy of Voriconazole Prophylaxis in Pediatric Patients with Acute Myeloid Leukemia, Single Center Experience, Egypt

Y. Madney, O. Arafah, H. Elmahalawy, Lobna Shalby
{"title":"Efficacy of Voriconazole Prophylaxis in Pediatric Patients with Acute Myeloid Leukemia, Single Center Experience, Egypt","authors":"Y. Madney, O. Arafah, H. Elmahalawy, Lobna Shalby","doi":"10.11648/J.CRJ.20190702.15","DOIUrl":null,"url":null,"abstract":"Patients with hematologic malignancies are at higher risk for invasive fungal infections (IFI) mainly patients with acute myeloid leukemia. Antifungal prophylaxis can help to decrease the incidence of these infections and their related complications. Prospective study compared to historical control data included 136 newly diagnosed Acute Myeloid Leukemia patients treated at the National Cancer Institute, Cairo University from 2011 to 2014. The prospective group received primary Voriconazole compared to retrospective control regarding the infectious complications and incidence of fungal infection. Results showed that one hundred thirty-six (136) newly diagnosed pediatric AML patients were included in the study, 61 patients didn't receive antifungal prophylaxis (Non- prophylactic arm) while 75 patients received voriconazole prophylaxis (prophylactic arm). The median age among both groups was 5.5 years old. Thirty-one (50%) of the 61 patients in (non - prophylactic arm) and five (6.6%) of the 75 patients enrolled in group B (prophylactic arm) developed an invasive fungal infection. The most commonly affected sites were pulmonary (34/ 36) while fungal sinus infection was reported in 2 patients. Most patients develop an invasive fungal infection during the induction treatment phase. Primary prophylaxis with voriconazole had a highly statistically significant impact on the reduction of incidence of invasive fungal infection between 2 groups (p value.001). Fungal attributable mortality was reported in 8 patients (13%) in the historical group (no antifungal prophylaxis) in comparison to 2 patients (2.6%) in group patients received voriconazole antifungal prophylaxis. Three Overall and Event-free survival were comparable between both groups. In conclusion, Prophylactic Voriconazole significantly decreased the incidence of fungal infections but it had no impact on diseases or overall survival outcome. Bacterial sepsis and disease-related mortality was the main cause of deaths among our group patients.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of leukemia (Los Angeles, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/J.CRJ.20190702.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Patients with hematologic malignancies are at higher risk for invasive fungal infections (IFI) mainly patients with acute myeloid leukemia. Antifungal prophylaxis can help to decrease the incidence of these infections and their related complications. Prospective study compared to historical control data included 136 newly diagnosed Acute Myeloid Leukemia patients treated at the National Cancer Institute, Cairo University from 2011 to 2014. The prospective group received primary Voriconazole compared to retrospective control regarding the infectious complications and incidence of fungal infection. Results showed that one hundred thirty-six (136) newly diagnosed pediatric AML patients were included in the study, 61 patients didn't receive antifungal prophylaxis (Non- prophylactic arm) while 75 patients received voriconazole prophylaxis (prophylactic arm). The median age among both groups was 5.5 years old. Thirty-one (50%) of the 61 patients in (non - prophylactic arm) and five (6.6%) of the 75 patients enrolled in group B (prophylactic arm) developed an invasive fungal infection. The most commonly affected sites were pulmonary (34/ 36) while fungal sinus infection was reported in 2 patients. Most patients develop an invasive fungal infection during the induction treatment phase. Primary prophylaxis with voriconazole had a highly statistically significant impact on the reduction of incidence of invasive fungal infection between 2 groups (p value.001). Fungal attributable mortality was reported in 8 patients (13%) in the historical group (no antifungal prophylaxis) in comparison to 2 patients (2.6%) in group patients received voriconazole antifungal prophylaxis. Three Overall and Event-free survival were comparable between both groups. In conclusion, Prophylactic Voriconazole significantly decreased the incidence of fungal infections but it had no impact on diseases or overall survival outcome. Bacterial sepsis and disease-related mortality was the main cause of deaths among our group patients.
伏立康唑预防小儿急性髓性白血病的疗效,单中心经验,埃及
血液系统恶性肿瘤患者发生侵袭性真菌感染(IFI)的风险更高,主要是急性髓系白血病患者。抗真菌预防有助于降低这些感染及其相关并发症的发生率。与历史对照数据相比的前瞻性研究包括2011年至2014年在开罗大学国家癌症研究所接受治疗的136名新诊断的急性髓细胞白血病患者。前瞻性组在感染并发症和真菌感染发生率方面接受了原发性伏立康唑治疗,与回顾性对照组进行了比较。结果显示,研究中包括了136名新诊断的儿童AML患者,61名患者没有接受抗真菌预防(非预防性组),75名患者接受了伏立康唑预防(预防组)。两组患者的中位年龄均为5.5岁。61名(非预防性组)患者中有31名(50%)和75名(预防性组(B组))患者中的5名(6.6%)出现侵袭性真菌感染。最常见的感染部位是肺部(34/36),而真菌窦感染报告有2例。大多数患者在诱导治疗阶段出现侵袭性真菌感染。伏立康唑一级预防对两组间侵袭性真菌感染发生率的降低具有高度统计学意义(p值.001)。据报道,历史组(无抗真菌预防)中有8名患者(13%)死于真菌,而接受伏立康唑抗真菌预防的组有2名患者(2.6%)死于真菌。三组患者的总体生存率和无事件生存率具有可比性。总之,预防性伏立康唑显著降低了真菌感染的发生率,但对疾病或总体生存结果没有影响。细菌性败血症和疾病相关死亡率是我们组患者死亡的主要原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信